Definitive Contract 75N93019C00047
Award Date
9/9/19
Potential Completion Date
9/29/21
Potential Value
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Silver Lake Research Corporation
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Irwindale, CA, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Silver Lake Research Corporation, doing business as Silver Lake Research Corp., has been awarded a firm fixed price definitive contract valued at $600,000 by the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this contract, Silver Lake will deliver EAP-derived monoclonal antibodies for immune targets involved in cell activation in hamsters, as requested in the original solicitation. The prime contractor will perform work in Irwindale, California....
This is a Definitive Contract awarded by the Centers for Disease Control and Prevention (CDC) to Silver Lake Research Corporation, a small business manufacturer of rapid testing innovations. The $466,200 Firm Fixed Price contract is for the development of "HYPERSPECIFIC MONOCLONAL ANTIBODIES AND LATERAL FLOW ASSAYS" and does not have a set-aside designation. Silver Lake Research Corporation is also the recipient of prime federal contracts and grants from agencies such as the National...
The Department of Homeland Security Science and Technology Directorate awarded a firm-fixed-price contract valued at $1,656,989.53 to Silver Lake Research Corporation, a for-profit organization and manufacturer of goods, for the rapid detection of high-priority foreign animal pathogens using enzyme-linked immunosorbent assay (ELISA)-derived hyperspecific monoclonal antibodies. This contract, which does not have a set-aside designation, is for the development of rapid testing innovations,...
This is a Cost Plus Fixed Fee contract awarded by the U.S. Department of Homeland Security (DHS) Science and Technology Directorate to Silver Lake Research Corporation, a small business, for research and development services related to the generation, validation, and characterization of new monoclonal antibodies reactive with a group of toxins. The contract has a ceiling value of $1,167,200.00 and an ultimate completion date of December 31, 2019. This award does not have a set-aside designation....
This is a federal contract awarded by the U.S. Department of Homeland Security (DHS) Science and Technology Directorate to Silver Lake Research Corporation, a for-profit small business manufacturer. The $999,169.20 cost-plus-fixed-fee contract is for research and development services to create and validate small molecule select agent toxin detection assays. The contract has an ultimate completion date of July 21, 2020 and was awarded on December 31, 2015. This contract is not set aside for any...
This is a $24,617.45 firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), to Meso Scale Diagnostics LLC, a for-profit limited liability company. The contract is for screening monoclonal antibodies against proteins of interest, with a period of performance through July 31, 2024. No small business set-aside was used. Meso Scale Diagnostics is an...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Lakepharma, Inc., a minority-owned, for-profit biopharmaceutical contract development and manufacturing organization (CDMO). The $20,000 contract is for the "heavy and light humanization of 1B3 MAB", which involves antibody humanization services to support NIAID's medical research and healthcare mission. The...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Lakepharma, Inc., a minority-owned, for-profit Contract Development and Manufacturing Organization (CDMO). The $12,999 contract is for DNA scale-up services sufficient for 0.5L production to support the agency's medical research and healthcare mission. The contract has no set-aside designation and was awarded on September 2, 2020 with an...
This is a $544,000.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Southern Research Institute, a corporate entity tax-exempt non-profit organization. The contract is for biomedical (applied/exploratory) research and does not have a set-aside designation. Through this contract, Southern Research Institute is providing a range of services, including drug discovery and...
<p>The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $7.75 million delivery order contract to Sri International for animal model development and efficacy testing of candidate monoclonal antibodies. The prime contractor, Sri International, will perform this work at its facility located at West Menlo Park, California over a two year period ending September 2029. The contract uses a cost plus fixed fee pricing arrangement.</p>